News
Epitopea Closes USD $31 million Pre-Series A Financing
Epitopea Closes USD $31 million Pre-Series A Financing
Find Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of FTX-101
Find Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of FTX-101
AstraZeneca Closes Acquisition of Amolyt Pharma
AstraZeneca Closes Acquisition of Amolyt Pharma
Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b
Amolyt Pharma Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
Amolyt Pharma Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company
enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company
Ironwood Enters into Definitive Agreement to Acquire VectivBio
Ironwood Enters into Definitive Agreement to Acquire VectivBio
Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study
Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study